Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF‑β signaling

Lu,Huimin; Ye,Jun; Zhang,Ling; Li,Mao; Lu,Shan; Yang,Dujiang; Hu,Weiming

doi:10.3892/mmr.2019.10699

Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF‑β signaling

Authors:
- Huimin Lu
- Jun Ye
- Ling Zhang
- Mao Li
- Shan Lu
- Dujiang Yang
- Weiming Hu
View Affiliations

Affiliations: Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: September 24, 2019 https://doi.org/10.3892/mmr.2019.10699
Pages: 4533-4539
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

LINC01638 is a long non‑coding RNA (lncRNA) with an oncogenic role in breast cancer, while its involvement in other malignancies is unknown. This study was performed to investigate the potential role of LINC01638 in pancreatic ductal adenocarcinoma (PDAC). The expression of LINC01638 was determined via reverse transcription‑quantitative polymerase chain reaction analysis, whereas the levels of transforming growth factor‑β1 (TGF‑β1) in plasma were measured via ELISA. Receiver operating characteristic curve analysis was conducted to determine the diagnostic value of LINC01638. Additionally, the migratory and invasive abilities of cells were evaluated via Transwell migration and invasion assays. In the present study, LINC01638 was significantly upregulated in tumor tissues compared with adjacent healthy tissues in the majority of patients with PDAC. Plasma levels of LINC01638 were significantly higher in patients with PDAC compared with in healthy controls. In effect, upregulation of plasma LINC01638 distinguished patients with PDAC from healthy controls in receiver operating characteristic analysis. Plasma levels of LINC01638 and TGF‑β1 were positively correlated in patients with PDAC, but not in healthy controls. LINC01638 overexpression increased TGF‑β1 expression, while silencing of LINC01638 using short hairpin RNA (shRNA) led to reduced TGF‑β1 expression in a PDAC cell line. LINC01638 overexpression promoted, while shRNA silencing inhibited, migration and invasion of cell of a PDAC cell line. Treatment with exogenous TGF‑β1 attenuated the inhibitory effect of LINC01638 shRNA silencing on cancer cell migration and invasion. It is concluded that LINC01638 lncRNA may be involved in the migration and invasion of PDAC cells via regulation of TGF‑β1.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
3	Gallmeier E and Gress TM: Pancreatic ductal adenocarcinoma. Internist (Berl). 59:805–822. 2018.(In German). View Article : Google Scholar : PubMed/NCBI
4	Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, et al: Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure. Surgery. 152 (3 Suppl 1):S43–S49. 2012. View Article : Google Scholar : PubMed/NCBI
5	Adamska A, Domenichini A and Falasca M: Pancreatic ductal adenocarcinoma: Current and evolving therapies. Int J Mol Sci. 18(pii): E13382017. View Article : Google Scholar : PubMed/NCBI
6	Ishiwata T: Pancreatic ductal adenocarcinoma: Basic and clinical challenges for better prognosis. J Carcinog Mutagene. S9:0052013.
7	Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C and Grippo PJ: TGF-β: Duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 6:djt3692014. View Article : Google Scholar
8	Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR and Blobe GC: TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis. 37:1041–1051. 2016. View Article : Google Scholar : PubMed/NCBI
9	Thakur AK, Nigri J, Lac S, Leca J, Bressy C, Berthezene P, Bartholin L, Chan P, Calvo E, Iovanna JL, et al: TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma. Cell Death Differ. 23:1358–1370. 2016. View Article : Google Scholar : PubMed/NCBI
10	Zhu Z, Xu Y, Zhao J, Liu Q, Feng W, Fan J and Wang P: miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-β signalling pathway. Br J Cancer. 112:1367–1375. 2015. View Article : Google Scholar : PubMed/NCBI
11	Luo L, Tang H, Ling L, Li N, Jia X, Zhang Z, Wang X, Shi L, Yin J, Qiu N, et al: LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. Oncogene. 37:6166–6179. 2018. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Zhou Y, Gong B, Jiang ZL, Zhong S, Liu XC, Dong K, Wu HS, Yang HJ and Zhu SK: Microarray expression profile analysis of long non-coding RNAs in pancreatic ductal adenocarcinoma. Int J Oncol. 48:670–680. 2016. View Article : Google Scholar : PubMed/NCBI
14	Fu XL, Liu DJ, Yan TT, Yang JY, Yang MW, Li J, Huo YM, Liu W, Zhang JF, Hong J, et al: Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Sci Rep. 6:335352016. View Article : Google Scholar : PubMed/NCBI
15	Zhu Z, Zhou J, Zhang Z and Li D: Decreased expression of lncRNA TMED11P is correlated with progression and prognosis in pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol. 9:10550–10556. 2016.
16	Ye Y, Chen J, Zhou Y, Fu Z, Zhou Q, Wang Y, Gao W, Zheng S, Zhao X, Chen T and Chen R: High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma. J Transl Med. 13:1372015. View Article : Google Scholar : PubMed/NCBI
17	Poruk KE, Blackford AL, Weiss MJ, Cameron JL, He J, Goggins M, Rasheed ZA, Wolfgang CL and Wood LD: Circulating tumor cells expressing markers of tumor-initiating cells predict poor survival and cancer recurrence in patients with pancreatic ductal adenocarcinoma. Clin Cancer Res. 23:2681–2690. 2017. View Article : Google Scholar : PubMed/NCBI
18	Liu JH, Chen G, Dang YW, Li CJ and Luo DZ: Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues. Asian Pac J Cancer Prev. 15:2971–2977. 2014. View Article : Google Scholar : PubMed/NCBI
19	Blobe GC, Schiemann WP and Lodish HF: Role of transforming growth factor β in human disease. N Engl J Med. 342:1350–1358. 2000. View Article : Google Scholar : PubMed/NCBI
20	Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC, et al: A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 25:666–681. 2014. View Article : Google Scholar : PubMed/NCBI
21	Li Z, Dong M, Fan D, Hou P, Li H, Liu L, Lin C, Liu J, Su L, Wu L, et al: lncRNA ANCR down-regulation promotes TGF-β-induced EMT and metastasis in breast cancer. Oncotarget. 8:67329–67343. 2017.PubMed/NCBI